We are delighted to present INOVIQ’s Annual Report for the financial year ended 30 June 2023. During this time, the Company made significant advances in its strategic initiatives and delivered key technical, development and commercial milestones. STRATEGIC FOCUS INOVIQ remained focused on advancing the development and commercialisation of its SubB2M cancer detection and EXO-NET exosome isolation platforms during FY23. This focused approach sought to validate our core technologies and establish a broad multi-product cancer diagnostic pipeline with multiple partnering prospects. These strategic initiatives achieved clinical validation of the SubB2M/CA15-3 test for breast cancer detection and a commercial partnership with Promega Corporation for our EXO-NET exosome capture technology. These milestones significantly de-risked INOVIQ’s core technologies, drove early EXO-NET revenues, advanced our SubB2M diagnostics pipeline toward commercial viability, and expanded our future partnering opportunities. SUBB2M TECHNOLOGY CLINICALLY VALIDATED The SubB2M technology was analytically and clinically validated by contract research organisation ResearchDx, demonstrating that the SubB2M/ CA15-3 test accurately detects breast cancer and outperforms a leading approved CA15-3 test. The test has excellent performance with 81% sensitivity and 93% specificity for detection of breast cancer across all stages. The next steps for the SubB2M/CA15-3 test are completing a cross-sectional breast cancer monitoring study and securing a CLIA-accredited laboratory partner in the US for commercialisation of the test as a Laboratory Developed Test in 2024. EXO-NET TECHNOLOGY IN-MARKET AND COMMERCIAL DEAL EXECUTED The introduction of INOVIQ’s EXO-NET pan-exosome capture tool to the US market in October 2022 with contract sales organisation Percorso Life Sciences was important to our commercialisation strategy. Dear INOVIQ Shareholders We are delighted to present INOVIQ’s Annual Report for the financial year ended 30 June 2023. Chairman and CEO Letter INOVIQ’s mission is to develop next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives PRECISION FOCUS Precision diagnostic and exosome solutions to improve patients lives DISRUPTIVE TECHNOLOGY Proprietary technology platforms driving future products for cancer and other diseases DEEP PIPELINE Multi-stage pipeline including SubB2M diagnostics, exosome research tools and exosome diagnostics COMPELLING DATA Industry leading data for exosome isolation tools, and diagnostics for breast and ovarian cancers COMMERCIAL PRODUCTS Commercial exosome isolation tools and bladder cancer detection test PARTNERING FOR GROWTH Partnering with KOLs and Industry to deliver clinical and commercial outcomes 2 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3